Things are looking up for pharma giant Astrazeneca, Liberum analysts have said. Recent drug trials have driven the firm's shares back up to where they were before high-profile problems connected with the failure of lung cancer drug Imfinzi. Analysts downgrade the firm to a "hold" but hike Astra's target price to 5,000P.
Analysts from Cantor Fitzgerald praised home furnishings firm Dunelm for investing in growth over the last year. Such investment is paying dividends already, they say, with sales set to grow to over £2bn in the medium-term. Cantor brokers stick to their "buy" rating and target price of 780p.
(c) 2017 City A.M., source Newspaper